Clinical trials · Washington, D.C., DC
Advanced Breast Cancer clinical trials in Washington, D.C.
We’re tracking 117 recruiting advanced breast cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Annapolis, MarylandAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT07206888Enrolling by invitation
Study to try advanced ultrasound for breast imaging
This study explores a new way to process ultrasound images of the breast. It is for women who have a finding, cyst, mass, or calcifications seen on a mammogram or ultrasound, and it uses a special ultrasound technique that may provide clearer images without extra radiation.
Baltimore, MarylandAges 18 years+ - NCT02422641RecruitingPhase 2
High-dose methotrexate for breast cancer in the brain lining
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Baltimore, MarylandAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Baltimore, MarylandAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Baltimore, MarylandAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Baltimore, MarylandAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Baltimore, MarylandAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Baltimore, MarylandAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Baltimore, MarylandAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Baltimore, MarylandAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Izalontamab Brengitecan vs chemo for certain breast cancers
This trial tests a new drug called Izalontamab Brengitecan against standard chemotherapy for people with untreated advanced triple-negative or ER-low breast cancer who cannot take certain immunotherapy drugs.
Baltimore, MarylandAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Baltimore, MarylandAges 18 years+ - NCT06016738RecruitingPhase 3
Palazestrant vs standard therapy for advanced breast cancer
This trial compares a new oral drug, palazestrant (OP-1250), to standard hormone therapies for people with ER+/HER2- advanced breast cancer that has worsened after prior hormone therapy. It tests whether palazestrant can better control the cancer.
Baltimore, MarylandAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Baltimore, MarylandAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Frederick, MarylandAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Fredericksburg, VirginiaAges 18 years+
Hear when a new Advanced Breast Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Advanced Breast Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting advanced breast cancer studies listed above.
- Johns Hopkins University · 6 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 4 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 2 studies
- Clinical Trial Site
- Frederick Health Hospital
- Hematology Oncology Associates of Fredericksburg
- Johns Hopkins Hospital
- Local Institution - 1035
What taking part in a advanced breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there advanced breast cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 117 recruiting advanced breast cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced breast cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced breast cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.